Efficacy of Noom Weight
biochemistryA reduction, weight loss, NAFLD Fibrosis, liver disease
INSULIN RESISTANCE, LIVER DISEASE
After 16 weeks, NW significantly decreased body weight when compared to standard clinical care (-5.5±5.8 kg vs. -0.3±4.6 kg, Change in body weight comparing Noom Weight with Standard Clinical Care. (A) After 16 weeks, NW significantly decreased body weight when compared to standard clinical care (-5.4±5.0% vs. -0.4±4.5%, Percent of patients achieving clinically significant body weight loss comparing Noom Weight with Standard Clinical Care. Three times more NW subjects achieved a clinically significant weight loss of Outcome measures: noninvasive assessment of liver disease severity and anthropometricsBody weight and BMI were significantly reduced in the NW group. Three times more patients achieved clinically significant body weight loss with NW.Both between-group and within-group comparisons were performed. Continuous end points were analyzed with the use of 2-sample and paired Abbreviations: BMI indicates body mass index; FIB-4, Fibrosis-4 index; NFS, NAFLD Fibrosis Score.Outcome measures: biochemistryA reduction in platelet count was observed with NW, otherwise, no statistically significant changes were observed in the laboratories obtained through chart review.Both between-group and within-group comparisons were performed. Continuous end points were analyzed with the use of 2-sample reported as mean±SDALT indicates alanine aminotransferase; AST, aspartate aminotransferase; DBP, diastolic blood pressure; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low density lipoprotein; SBP, systolic blood pressure; WBC, white blood cell.